DN

Dipanjan Nath

Active Director Director DIN 08117128
DIN 08117128 First appointment Apr 2018 Primary industry Electrnoics
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2018
Shareholding value •••• Premium profile

About Dipanjan Nath

Data last updated:

Dipanjan Nath is a Director at Often Pharmaceuticals Private Limited (since 2018). The company operates in Electrnoics. Often Pharmaceuticals Private Limited reported revenue of ₹28,763 (FY 2023).

DIN 08117128
Primary Designation Director
Industry Electrnoics
First Appointment 23 Apr 2018
Oldest Company Age 8 yrs
Largest company Often Pharmaceuticals Private Limited · ₹28,763 (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director23 Apr 20182018₹28,763 (FY 2023)Active

Board colleagues of Dipanjan Nath

NameDINCompanyDesignation
Sumita Bera08117129Often Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Often Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Dipanjan Nath

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dipanjan Nath

Dipanjan Nath currently holds 1 directorship: Often Pharmaceuticals Private Limited (Director, since 23 Apr 2018, revenue ₹28,763 (FY 2023)).

Dipanjan Nath was first appointed on 23 Apr 2018 as Director at Often Pharmaceuticals Private Limited.

The current boards of Dipanjan Nath's companies include Sumita Bera (Often Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available